Imipramine
TCAs
Tricyclic antidepressants (TCAs)
The first tricyclic antidepressant. Used for depression and, in children, for bedwetting; anticholinergic and dangerous in overdose.
Quick facts
- Group
- Tricyclic antidepressants (TCAs)
- Target
- Serotonin transporter (SERT) and noradrenaline transporter (NET)
- Used for
- Depression · Bedwetting in children · Off-label
- Key effects
- Dry mouth · Drowsiness · Dizziness on standing
- Monitor
- Mood · Pulse · Eye examination before starting
- ATC
- N06AA02
No doses: the clinician sets them by the current guideline.
Mechanism of action
The figure shows imipramine bound to the human serotonin transporter (cryo-EM; vilazodone and an antibody fragment are also present).
Imipramine, a tertiary-amine tricyclic, blocks the reuptake of both serotonin and noradrenaline; it also has an active metabolite that lasts longer than the parent drug. More transmitter stays in the synapse and receptors adapt over weeks, which relieves depression. It also blocks muscarinic, histamine H1 and alpha-1 receptors and cardiac sodium channels: dry mouth, sedation, orthostatic hypotension and, in overdose, arrhythmias. How it reduces bedwetting is not fully explained.
- Blocks serotonin and noradrenaline reuptake
- An active metabolite prolongs the effect
- Receptor adaptation over weeks relieves depression
- Off-target: muscarinic, H1, alpha-1 block and Na+ channels
Indications
- Depression Major depressive disorder →
- Bedwetting in children (tablets only) Nocturnal enuresis →
- Off-label: panic disorder Panic disorder →
Adverse effects
Common
- Dry mouth, constipation and difficulty passing urine
- Drowsiness, tiredness, nightmares
- Dizziness on standing
- Sweating; appetite or weight change
- Changes in sex drive or ability
Contraindications
- MAO inhibitors now or within the previous two weeks
- Recent heart attack
- Generally avoided in people aged 65 or older
Key interactions
- MAO inhibitors, linezolid, methylene blue
- Serotonin syndrome and severe reactions; not combined.
- Cimetidine
- Raises imipramine levels.
- Alcohol
- More drowsiness.
- Tobacco smoking
- May reduce its effect.
What is monitored
- Mood, agitation and suicidal thoughts, especially early
- Pulse, blood pressure and ECG when there is heart disease
- Eye examination before starting
- Signs of infection or jaundice
Administration and safety
- Oral; for bedwetting it is given about an hour before bedtime.
- Started low and raised gradually; not stopped suddenly.
- Kept out of children's reach: a small number of tablets can be fatal.
Pregnancy and breastfeeding
Pregnancy or plans for pregnancy are discussed with the prescriber; it is used only when the benefit justifies the possible risk.
Nursing care
- Before: screen for heart disease, glaucoma, urinary retention, seizures and MAOI use.
- During: ask about mood and suicidal thoughts; tell families what to watch for.
- Check lying and standing blood pressure; teach to rise slowly.
- Teach sun protection and to avoid alcohol.
Pharmacokinetics
- Absorption
- Oral.
- Metabolism
- Liver, to an active metabolite with a longer half-life.
- Onset and duration
- Benefit in depression may take one to three weeks or longer.
Test yourself
Think of the answer, then tap the question to see it.
Which two transporters does imipramine block?
The serotonin transporter (SERT) and the noradrenaline transporter (NET).
Which childhood condition can imipramine tablets treat?
Bedwetting (nocturnal enuresis).
Why is imipramine generally avoided in older adults?
Anticholinergic effects, sedation and orthostatic hypotension raise the risk of confusion and falls; safer options exist.
Connections
← Back to the class: Tricyclic antidepressants (TCAs)
Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.
Sources: Imipramine: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); Cryo-EM structure of the wild-type human serotonin transporter complexed with vilazodone, imipramine and 15B8 Fab (RCSB Protein Data Bank, 2021); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
